Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1986 Jul;78(1):303–309. doi: 10.1172/JCI112565

Retinoids. Structure-function relationship in normal and leukemic hematopoiesis in vitro.

A Tobler, M I Dawson, H P Koeffler
PMCID: PMC329562  PMID: 3459735

Abstract

Retinoids were studied both to identify what skeletal components are important in the modulation of normal and leukemic human myeloid clonal proliferation and differentiation in vitro and to elucidate the mechanism by which retinoids modulate proliferation of hematopoietic cells. Retinoids with a derivatized terminal carboxyl group were significantly less active than all-trans-retinoic acid, and those with the addition of two methyl groups to the cyclohexenyl ring of retinoic acid or substitution of its beta-cyclogeranylidene group with a 1,1,3,3-5-indanyl ring system were markedly more active than all-trans-retinoic acid. Five of the retinoids strongly inhibited clonal growth of the HL-60 and KG-1 human leukemic cell lines (50% inhibition in the range of 3 X 10(-10)-1 X 10(-8) M) and markedly stimulated normal human myeloid colony formation (granulocyte-macrophage colony-forming cells [GM-CFC] 150% stimulation in the range of 3 X 10(-9)-3 X 10(-8) M). Further studies suggested that: Common structural requirements of the retinoids were important in the modulation of both normal and leukemic hematopoiesis. The retinoids were able to inhibit leukemic proliferation without induction of differentiation of the neoplastic cells. Studies on normal human GM-CFC suggested that the retinoids did not act by themselves as a colony-stimulating factor (CSF), or by stimulating accessory cells to produce CSF, but either required earlier progenitor cells to become GM-CFC or enhanced the sensitivity of GM-CFC to the action of CSF.

Full text

PDF
303

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baehner R. L., Boxer L. A., Davis J. The biochemical basis of nitroblue tetrazolium reduction in normal human and chronic granulomatous disease polymorphonuclear leukocytes. Blood. 1976 Aug;48(2):309–313. [PubMed] [Google Scholar]
  2. Breitman T. R., Selonick S. E., Collins S. J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A. 1980 May;77(5):2936–2940. doi: 10.1073/pnas.77.5.2936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Collins S. J., Gallo R. C., Gallagher R. E. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature. 1977 Nov 24;270(5635):347–349. doi: 10.1038/270347a0. [DOI] [PubMed] [Google Scholar]
  4. Di Persio J. F., Brennan J. K., Lichtman M. A., Speiser B. L. Human cell lines that elaborate colon-stimulating activity for the marrow cells of man and other species. Blood. 1978 Mar;51(3):507–519. [PubMed] [Google Scholar]
  5. Douer D., Koeffler H. P. Retinoic acid enhances colony-stimulating factor-induced clonal growth of normal human myeloid progenitor cells in vitro. Exp Cell Res. 1982 Mar;138(1):193–198. doi: 10.1016/0014-4827(82)90105-7. [DOI] [PubMed] [Google Scholar]
  6. Douer D., Koeffler H. P. Retinoic acid enhances growth of human early erythroid progenitor cells in vitro. J Clin Invest. 1982 Apr;69(4):1039–1041. doi: 10.1172/JCI110507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Douer D., Koeffler H. P. Retinoic acid. Inhibition of the clonal growth of human myeloid leukemia cells. J Clin Invest. 1982 Feb;69(2):277–283. doi: 10.1172/JCI110450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gasson J. C., Weisbart R. H., Kaufman S. E., Clark S. C., Hewick R. M., Wong G. G., Golde D. W. Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. Science. 1984 Dec 14;226(4680):1339–1342. doi: 10.1126/science.6390681. [DOI] [PubMed] [Google Scholar]
  9. Gold E. J., Mertelsmann R. H., Itri L. M., Gee T., Arlin Z., Kempin S., Clarkson B., Moore M. A. Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes. Cancer Treat Rep. 1983 Nov;67(11):981–986. [PubMed] [Google Scholar]
  10. Golde D. W., Quan S. G., Cline M. J. Human T lymphocyte cell line producing colony-stimulating activity. Blood. 1978 Nov;52(5):1068–1072. [PubMed] [Google Scholar]
  11. Ichikawa Y. Differentiation of a cell line of myeloid leukemia. J Cell Physiol. 1969 Dec;74(3):223–234. doi: 10.1002/jcp.1040740303. [DOI] [PubMed] [Google Scholar]
  12. Koeffler H. P., Golde D. W. Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. Science. 1978 Jun 9;200(4346):1153–1154. doi: 10.1126/science.306682. [DOI] [PubMed] [Google Scholar]
  13. Koeffler H. P., Golde D. W. Human myeloid leukemia cell lines: a review. Blood. 1980 Sep;56(3):344–350. [PubMed] [Google Scholar]
  14. Lotan R., Neumann G., Lotan D. Relationships among retinoid structure, inhibition of growth, and cellular retinoic acid-binding protein in cultured S91 melanoma cells. Cancer Res. 1980 Apr;40(4):1097–1102. [PubMed] [Google Scholar]
  15. Moon R. C., McCormick D. L., Becci P. J., Shealy Y. F., Frickel F., Paust J., Sporn M. B. Influence of 15 retinoic acid amides on urinary bladder carcinogenesis in the mouse. Carcinogenesis. 1982;3(12):1469–1472. doi: 10.1093/carcin/3.12.1469. [DOI] [PubMed] [Google Scholar]
  16. Moon R. C., McCormick D. L., Mehta R. G. Inhibition of carcinogenesis by retinoids. Cancer Res. 1983 May;43(5 Suppl):2469s–2475s. [PubMed] [Google Scholar]
  17. Moon R. C., Thompson H. J., Becci P. J., Grubbs C. J., Gander R. J., Newton D. L., Smith J. M., Phillips S. L., Henderson W. R., Mullen L. T. N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res. 1979 Apr;39(4):1339–1346. [PubMed] [Google Scholar]
  18. Newton D. L., Henderson W. R., Sporn M. B. Structure-activity relationships of retinoids in hamster tracheal organ culture. Cancer Res. 1980 Oct;40(10):3413–3425. [PubMed] [Google Scholar]
  19. Sachs L. Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia. Nature. 1978 Aug 10;274(5671):535–539. doi: 10.1038/274535a0. [DOI] [PubMed] [Google Scholar]
  20. Sani B. P., Dawson M. I., Hobbs P. D., Chan R. L., Schiff L. J. Relationship between binding affinities to cellular retinoic acid-binding protein and biological potency of a new series of retinoids. Cancer Res. 1984 Jan;44(1):190–195. [PubMed] [Google Scholar]
  21. Sani B. P., Meeks R. G. Subacute toxicity of all-trans- and 13-cis-isomers of N-ethyl retinamide, N-2-hydroxyethyl retinamide, and N-4-hydroxyphenyl retinamide. Toxicol Appl Pharmacol. 1983 Sep 15;70(2):228–235. doi: 10.1016/0041-008x(83)90098-4. [DOI] [PubMed] [Google Scholar]
  22. Segal A. W. Nitroblue-tetrazolium tests. Lancet. 1974 Nov 23;2(7891):1248–1252. doi: 10.1016/s0140-6736(74)90758-2. [DOI] [PubMed] [Google Scholar]
  23. Sporn M. B., Dunlop N. M., Newton D. L., Henderson W. R. Relationships between structure and activity of retinoids. Nature. 1976 Sep 9;263(5573):110–113. doi: 10.1038/263110a0. [DOI] [PubMed] [Google Scholar]
  24. Strickland S., Breitman T. R., Frickel F., Nürrenbach A., Hädicke E., Sporn M. B. Structure-activity relationships of a new series of retinoidal benzoic acid derivatives as measured by induction of differentiation of murine F9 teratocarcinoma cells and human HL-60 promyelocytic leukemia cells. Cancer Res. 1983 Nov;43(11):5268–5272. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES